Lakefront Biotherapeutics (LKFT) Revenue (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Revenue data on file, last reported at $7.6 million in Q1 2026.

• On a quarterly basis, Revenue fell 90.38% year-over-year to $7.6 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 398.27% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 339.54% from the prior year.
• Revenue for Q1 2026 stood at $7.6 million, down from $1.0 billion in the prior quarter.
• Over the last five years, Revenue for LKFT reached as high as $1.0 billion in Q4 2025 and fell as low as -$55.1 million in Q2 2024.
• Historically, Revenue has averaged $122.9 million across 5 years, with a median of $66.6 million in 2023.
• Across the five-year window, Revenue plunged 184.3% in 2024 and soared 8432.91% in 2025, its largest moves.
• Year by year, Revenue stood at $184.4 million in 2022, then plunged by 34.48% to $120.8 million in 2023, then sank by 89.83% to $12.3 million in 2024, then surged by 8432.91% to $1.0 billion in 2025, then tumbled by 99.28% to $7.6 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $7.6 million in Q1 2026, $1.0 billion in Q4 2025, and $83.2 million in Q3 2025.